all report title image
  • Published On : Jan 2023
  • Code : CMI5483
  • Industry : Pharmaceutical
  • Pages : 180
  • Formats :

Heparin calcium is an anticoagulant which is oindicated for the prevention and treatment of thrombotic events such as pulmonary embolism, deep vein thrombosis, and others. Unfractionated and low molecular weight heparin are the two form of heparin calcium. Unfractionated heparin is a fast acting blood thinner that acts with antithrombin and blocks the clotting of blood, whereas,  unfractionated heparin doesn’t break down the blood clots. It keeps them from growing and stops the formationnof new one, after the administration of intravenous unfractionated heparin

The global heparin calcium market is estimated to be valued at US$ 1,370.9 million in 2022 and is expected to exhibit a CAGR of 2.7% during the forecast period (2022-2030).

Analysts’ Views on Global Heparin Calcium Market:

The heparin calcium market's growth can be hindered by the treatment gaps in atrial fibrillation. Heparin calcium is the most commonly used anticoagulant for deep vein thromvosis. For instance, in February 2021, according to the data publisehed in National Center for Biotechnology Information, a cross-sectional, observational study was conducted on 40 centers across Lebanon and Jordan. It was stated that, 366 out of the total 704 patients used low molecular weight heparin for the deep vein thrombosis. Hence, it is concluded that low molecular weight heparin is the most commonly used anticoagulant.

Figure 1. Global Heparin Calcium Market Share (%), by Type, 2022

Heparin Calcium  | Coherent Market Insights

 Global Heparin Calcium Market – Driver

The increasing prevalence of diseases such as deep vein thrombosis is expected to drive the heparin calcium market over the forecast period.

The increasing prevalence of diseases such as deep vein thrombosis   is expected to drive the heparin calcium market over the forecast period. According to the data published in BMC Journal, in October 2021, a study was conducted among 225 adults at Affiliated Hospital of Shandong First Medical University in 2020, to identify the prevalence, risk factors, and prognosis of deep vein thrombosis. Hence, it was stated that 40% patients developed deep vein thrombosis due to lower serum creatinine levels and lower partial pressure of arterial oxygen.

CMI table icon

Heparin Calcium Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 1,370.9 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 2.7% 2030 Value Projection: US$ 1,700.8 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Type: Unfractionated Heparin, Low Molecular Weight Heparin
  • By Route of Administration: Intravenous, Subcutaneous
  • By Application: Kidney Dialysis, Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Others (Cardiac Surgery, etc.)
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 
Companies covered:

Sanofi, Pfizer Inc., Dongying Tiandong Pharmaceutical Co., Ltd., PANPHARMA S.A., Merck KGaA, Teva Pharmaceutical Industries Ltd., SMITHFIELD BIOSCIENCE, Afine Chemicals Limited, Yino Pharma Limited, Shandong Sheelian Pharmaceutical Co., Ltd., Aspen Holdings, Opocrin S.p.A.

Growth Drivers:
  • Ongoing research and development on heparin calcium by key market players
Restraints & Challenges:
  • Various side affects associated with the use of  heparin calcium 

Figure 2. Global Heparin Calcium Market Value (US$ Million), by Region, 2022

Heparin Calcium  | Coherent Market Insights

Global Heparin Calcium Market- Regional Analysis

Among regions, Europe is estimated to hold a dominant position in the heparin calcium market over the forecast period. Europe holds 40% of market share due to increasing number of pulmonary embolism disease in the reagion. According to data published by the journal of thrombosis and haemostatis, in October 2020, the prevalence of pulmonary embolism in Europe was 23% in the systematic review of 2019.

Moreover, according to the same source, The North America region is expected to hold a second largest position in heparin calcium market over the forecast period. The prevalence of pulmonary embolism in North America was 8% in the systematic review of 2019.

Global Heparin Calcium Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a positive impact on the global heparin calcium market. For instance, in May 2021, according to the data published in Journal of the American College of Cardiology, COVID-19 is associated with a high incidence of pulmonary embolism and deep vein thrombosis, the study was conducted to identify the incidence of pulmonary embolism and deep vein thrombosis from the medical records of 1,000 COVID-19 patients. Hence, it was stated that the cumulative incidence of pulmonary embolism and deep vein thrombosis were 1.8% and 2.5%, respectively in 2020. Thus, positively impacting the global heparin calcium market growth.

Global Heparin Calcium Market Segmentation:

The global heparin calcium market report is segmented into Type, Route of Administration, Application, and Distribution Channel

Based on Type, the market is segmented into unfractionated heparin and low molecular weight heparin. Out of which, low molecular weight heparin segment is expected to dominant position in heparin calcium market during the forecast period and this is attributed due to increase in the usage of low molecular weight heparin.

Based on Route of Administration, the market is segmented into an intravenous,and subcutaneous. Out of which, intravenous segment is expected to dominate the market over the forecast period and this is attributed due to increase in the use of intravenous for treatments of various disease such as deep vein thrombosis, pulmonary embolism, and others.  

Based on Application, the heparin calcium market is segmented into Kidney Dialysis, Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, and Others (Cardiac Surgery, etc.). Deep Vein Thrombosis segment is expected to dominate the market over the forecast period and this is attributed to the increasing prevalence of deep vein thrombosis.

Based on Distribution Channel, the heparin calcium market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Of which, hospital pharmacies segment is expected to dominate the market over the forecast period and this is attributed to the increase in number of hospital pharmacies.

Among all segmentation, application segment has highest potential due to increasing research and development by key market players for the treatment of deep vein thrombosis treatment. For instance, in November 2021, Sunnybrook Health Sciences Centre, in collaboration with LEO Pharma A/S, a pharmaceutical company, started a clinical trial for the treatment of deep vein thrombosis. The trial is expected to complete in October 2023.

Global Heparin Calcium Market Cross Sectional Analysis:

In distribution channel segment, hospital pharmacies held as a dominant segment in North America region due to the increasing number of hospital pharmacies. For instance, in January 2022, according to data provided by the National Association of Pharmacy Regulatory Authorities, there were 11,814 pharmacies in Canada till January 2022.

In application segment, deep vein thrombosis is dominant in Asia Pacific region due to increasing number product approval by the U.S. Food and Drug Administration. For instance, in May 2019, U.S. Food and Drug Administration approved Fragmin, an anticoagulant for subcutaneous use to reduce the recurrence of symptomatic deep vein thrombosis in pediatric patients one month of age and older.

Global Heparin Calcium Market: Key Developments

  • Ongoing research and development by key market players is expected to drive the heparin calcium market over the forecast period. For instance, in December 2022, Galician Research Group on Digestive Tumors in collaboration with LEO Pharma A/S, a pharmaceutical company, started a clinical trial for to evaluate the efficacy of tinzaparin (low molecular weight heparin) for the prevention of symptomatic venous thromboembolic disease. The trial is expected to complete in March 2025.
  • Increasing adoption of inorganic growth strategies such as product approval by regulatory authorities such as the U.S. Food and Drug Administration is expected to drive the global heparin calcium market growth over the forecast period. For instance, in June 2021, Boehringer Ingelheim Pharmaceuticals, Inc., a pharmaceutical company, announced that they had received an approval from the U.S. Food and Drug Administration for Dabigatran, an anticoagulant for children from 3 months to 11 years old to treat deep vein thrombosis.

Global Heparin Calcium Market: Key Trends

Ongoing Research and Development on calcium heparin is expected to drive the hea[prin calcium market over the forecast period.

Ongoing Research and Development on calcium heparin is expected to drive the hea[prin calcium market over the forecast period.For instance, on September 27, 2022, Anthos Therapeutics, a biopharmaceutical company, announced that they had started a clinical trial on Dalteparin, a low-molecular weight heparin, for the treatment of deep vein thrombosis.

Global Heparin Calcium Market: Restraint

Various side affects associated with the use of  heparin calcium is expected to hinder the global heparin calcium market over the forecast period.

Various side affects associated with the use of  heparin calcium is expected to hinder the global heparin calcium market over the forecast period. For instance, in August 2022, according to data published in MDPI Journal, Heparin is a widely used anticoagulant substance that increases the clotting time. But, using heparin is challenging due to its severe or life-threatening side effects such as heparin-induced thrombocytopenia and thrombosis. In addition, heparin is strongly electronegative and exhibits a binding affinity for the positive active sites of human serum proteins, biochemical pathway activations, which can negatively affect dialysis patients.

Global Heparin Calcium Market - Key Players

Major players operating in the global heparin calcium market include Sanofi, Pfizer Inc., Dongying Tiandong Pharmaceutical Co., Ltd., PANPHARMA S.A., Merck KGaA, Teva Pharmaceutical Industries Ltd., SMITHFIELD BIOSCIENCE, Afine Chemicals Limited, Yino Pharma Limited, Shandong Sheelian Pharmaceutical Co., Ltd., Aspen Holdings, Opocrin S.p.A.

Heparin calcium is calcium salt form of heparin. Heparin calcium is a negatively charged linear polysaccharide that belongs to the glycosaminoglycan family. Нeparin is an anticoagulant which is indicated for the prevention and treatment of thrombotic events such as pulmonary embolism, deep vein thrombosis and atrial fibrillation. As a glycosaminoglycan anticoagulant, heparin calcium binds to antithrombin III to form a heparin-antithrombin III complex. Heparin is also used to prevent excess coagulation during cardiac surgery, dialysis, and others. Heparin can be administered by intravenous or subcutaneous route. Unfractionated heparin and low molecular weight heparin are the two forms of calcium heparin. Subcutaneous heparin is administred to prevent thromboembolism and the administration of intravenous heparin is used for therapeutic anticoagulation. Bleeding, thrombocytopenia, injection site reactions, and other adverse effects are seen with chronic heparin administration. Bleeding is a major complication associated with heparin use. In long term use, unfractionated heparin has a higher risk of osteoporosis. Unfractionated heparin is more specific than low molecular weight heparin for thrombin and the effects of unfractionated heparin can typically be reversed by using protamine sulfate.

Market Dynamics

Increasing adoption of inorganic strategies such as launch of campaign, in order to raise awareness is expected to drive the global heparin calcium market growth over the forecast period. For instance, in November 2020, The Bristol Myers Squibb–Pfizer Alliance, announced that they had launched the ‘No Time to Wait’ awareness campaign, to raise awareness of the symptoms of deep vein thrombosis. This campaign helps people to find additional information about deep vein thrombosis. 

Key features of the study:

  • This report provides an in-depth analysis of the global heparin calcium market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global heparin calcium market based on the following parameters–company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Sanofi, Pfizer Inc., Dongying Tiandong Pharmaceutical Co., Ltd., PANPHARMA S.A., Merck KGaA, Teva Pharmaceutical Industries Ltd., SMITHFIELD BIOSCIENCE, Afine Chemicals Limited, Yino Pharma Limited, Shandong Sheelian Pharmaceutical Co., Ltd., Aspen Holdings, Opocrin S.p.A.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global heparin calcium market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global heparin calcium market

Detailed Segmentation:

  • Global Heparin Calcium Market, By Type:
    • Unfractionated Heparin
    • Low Molecular Weight Heparin
  • Global Heparin Calcium Market, By Route of Administration:
    • Intravenous
    • Subcutaneous
  • Global Heparin Calcium Market, By Application:
    • Kidney Dialysis
    • Atrial Fibrillation
    • Deep Vein Thrombosis
    • Pulmonary Embolism
    • Others (Cardiac Surgery, etc.)
  • Global Heparin Calcium Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Heparin Calcium Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Regions
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Sanofi*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Pfizer Inc.
    • Dongying Tiandong Pharmaceutical Co., Ltd.
    • PANPHARMA S.A.
    • Merck KGaA
    • Teva Pharmaceutical Industries Ltd.
    • SMITHFIELD BIOSCIENCE
    • Afine Chemicals Limited
    • Yino Pharma Limited
    • Shandong Sheelian Pharmaceutical Co., Ltd.
    • Aspen Holdings
    • Opocrin S.p.A.

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global heparin calcium market is estimated to be valued at US$ 1,370.9 million in 2022 and is expected to exhibit a CAGR of 2.7% between 2022 and 2030.
Factors such as ongoing research and development on heparin calcium by key market players are expected to drive the market.
Low molecular weight heparin is the leading type segment in the market
Various side affects associated with the use of  heparin calcium is expected to hinder the market over the forecast period
Major players operating in the market include Sanofi, Pfizer Inc., Dongying Tiandong Pharmaceutical Co., Ltd., PANPHARMA S.A., Merck KGaA, Teva Pharmaceutical Industries Ltd., SMITHFIELD BIOSCIENCE, Afine Chemicals Limited, Yino Pharma Limited, Shandong Sheelian Pharmaceutical Co., Ltd., Aspen Holdings, Opocrin S.p.A.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo